Dermorphin Guia & Tabela de Dose

What is Dermorphin?

Dermorphin is a tiny protein fragment — a heptapeptide, meaning it is built from just seven amino acids — first discovered in the 1980s in the skin of Amazonian frogs belonging to the Phyllomedusinae family.^[2] Its full sequence is Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH₂.^[1] What makes dermorphin unusual is that it contains a D-amino acid — a mirror-image building block rarely found in nature — which helps protect it from being broken down quickly by the body.^[4] Amazon tribes traditionally called it "Kambo" or "Sapo" and used frog secretions for ritual and hunting purposes.^[4] Today, dermorphin is classified as a research compound studied in preclinical (animal) models. It is not approved for human use.

How Dermorphin Works

Think of opioid receptors as locks on nerve cells. Dermorphin acts like a master key that fits very precisely into one specific lock called the mu-opioid receptor (MOR).^[2] When it binds there, it can dial down pain signals travelling through the nervous system. What makes dermorphin stand out is just how tightly and selectively it grips that lock — research suggests its binding affinity and pain-relieving potency exceed those of morphine in animal models.^[2]

Some dermorphin analogs (slightly modified versions) go a step further. They trigger the release of natural opioid-like chemicals called dynorphins inside the body, which then activate a second type of receptor — the kappa-opioid receptor. Researchers believe this two-step mechanism may reduce unwanted side effects like tolerance and dependence that are common with traditional opioids.^[1]

A peripherally acting analog called DALDA (Dermorphin [D-Arg2, Lys4] (1-4) amide) is designed to act mainly outside the brain, targeting opioid receptors in tissues like the skin, joints, and spinal cord periphery. This is significant because researchers hope it could deliver pain relief without the central nervous system side effects — like sedation or addiction — associated with drugs that act inside the brain.^[3]

What the Research Shows

Preclinical research has explored dermorphin and its analogs across several pain models:

• General analgesic profile: Early reviews established that dermorphin peptides are potent analgesics in rodents and primates, showing higher potency than morphine and a lower tendency to produce tolerance, dependence, or classic opioid side effects in chronic exposure studies.^[2]
• Burn pain (rat models): A 2025 study tested DALDA in rats with burn injury-induced chronic pain. Animals showed reduced sensitivity to mechanical, thermal, and cold stimuli. At higher doses, DALDA also relieved spontaneous (ongoing) pain. Researchers found it downregulated inflammatory proteins — including TRPV1, NR2B, TNF-α, and IL-6 — in the nervous system, suggesting it works partly by calming neuroinflammation. Importantly, no signs of addiction were observed at the doses tested.^[3]
• Postoperative pain (historical clinical data): In 1985, a randomized, placebo-controlled clinical trial found intrathecally administered dermorphin outperformed both placebo and morphine for postoperative pain — yet the study went largely unnoticed and was never followed up clinically.^[4]
• Palliative and cancer pain: Researchers have proposed revisiting dermorphin for intrathecal (spinal) use in terminal cancer patients, arguing its potency and favorable side-effect profile in animal data make it worth formal clinical re-evaluation.^[5]
• Horse pharmacokinetics: A veterinary pharmacology study gave horses dermorphin intravenously and intramuscularly. After IV dosing, a brief period of excitation and increased heart rate was observed, resolving within five minutes. The compound was detectable in plasma for up to 12 hours and in urine for up to 72 hours depending on the route. Bioavailability via intramuscular injection varied considerably between animals.^[6]

What Dermorphin Is Being Studied For

• Preclinical models of acute and chronic pain, including burn pain and post-surgical pain^[3][4]
• Development of mu-opioid agonists with fewer side effects than morphine^[1][2]
• Peripheral opioid receptor targeting to avoid central nervous system side effects^[3]
• Potential intrathecal applications for cancer-related and postoperative pain^[4][5]
• Veterinary pharmacology and sports-doping detection in horses^[6]

How Dermorphin Is Dosed in Research

Doses vary widely depending on the animal model, the specific analog (dermorphin itself versus DALDA), the administration route, and the research question being asked. For example, burn pain studies in rats used a range of DALDA doses, while the equine pharmacokinetics study used a very small microgram-per-kilogram amount given intravenously or intramuscularly. You can find all documented preclinical dose levels — including their units and contexts — in the dosage chart on this page. To explore weight-based scaling, use the calculator tool. These figures are strictly for research reference; they do not constitute dosing advice for humans.

Mixing and Storing Dermorphin

Like most research peptides, dermorphin typically arrives as a lyophilized (freeze-dried) powder in a sealed vial. To reconstitute it, researchers slowly add bacteriostatic water or sterile saline to the vial, letting the liquid run down the side rather than squirting it directly onto the powder. Swirl gently — never shake — until fully dissolved. Once mixed, the solution should be kept refrigerated (around 2–8 °C) and used within a few weeks; for longer storage, freezing at −20 °C is generally recommended. Avoid repeated freeze-thaw cycles, as these can degrade the peptide. Always work under sterile conditions, and inspect the solution for cloudiness or particles before any use. These are standard laboratory handling practices; consult applicable institutional protocols for your specific research setting.

Sources

1. Dermorphin tetrapeptide analogs as potent and long-lasting analgesics with pharmacological profiles distinct from morphine. — Peptides, 2011. PMID 21126548.
2. The dermorphin peptide family. — General pharmacology, 1996. PMID 8981054.
3. Dermorphin [D-Arg2, Lys4] (1-4) Amide Attenuates Burn Pain by Inhibiting TRPV1/NR2B Mediated Neuroinflammatory Signalling. — Molecular neurobiology, 2025. PMID 40442534.
4. Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation. — Journal of pain research, 2018. PMID 30538538.
5. Dermorphin: A Missed Palliative Care Opportunity for Intrathecal Therapy in Oncological Patients? — Pain medicine (Malden, Mass.), 2019. PMID 30986300.
6. Pharmacokinetics and pharmacodynamics of dermorphin in the horse. — Journal of veterinary pharmacology and therapeutics, 2015. PMID 25376170.